|
|
|
Abbott Enters Into Agreement With Cleveland Clinic for Myeloperoxidase (MPO) Cardiac Test
Myeloperoxidase (MPO) Test May Be Useful in Predicting Adverse Cardiac Events ABBOTT PARK, Ill., Feb. 7 -- Abbott announced today that it has entered into a licensing agreement with The Cleveland Clinic for the development of an automated in vitro diagnostic test to detect myeloperoxidase (MPO), an enzyme found in white blood cells. Detecting elevated, circulating levels of MPO may be useful in determining a person's risk for adverse cardiac events such as a heart attack. "The Cleveland Clinic's expertise and research in heart disease is well-known, and we are pleased to enter into this agreement. Heart disease is a major cause of death worldwide, and Abbott is committed to developing new cardiac diagnostic tests that could improve the diagnosis and treatment of patients with cardiovascular diseases," said William Brown, Ph.D., vice president, Diagnostic Assays and Systems Development, Abbott. Research conducted at The Cleveland Clinic and published in the Oct. 23, 2003 issue of The New England Journal of Medicine linked elevated MPO levels with the risk of heart attack. More than 600 patients presenting with chest pain in the emergency department were evaluated. MPO was identified as a strong predictor for major adverse cardiac events over the following 30-day to six-month period. The authors of the study concluded that MPO's link to inflammation in coronary arteries from unstable plaque could make it a potential biomarker useful for risk stratification in patients presenting with chest pain. "Today, cardiac diagnostic tests already influence how treatment recommendations are made. The potential of an MPO test to help identify patients at risk for a major cardiac event in the near term could prove to be another advance in patient care," said Stanley Hazen, M.D., Ph.D., head of the Section of Preventive Cardiology and Cardiac Rehabilitation at The Cleveland Clinic. Under the terms of the agreement, Abbott obtains non-exclusive rights to The Cleveland Clinic's existing technologies relating to MPO as a risk indicator for cardiovascular disease. Abbott also maintains worldwide rights to commercialize products using this technology. PrognostiX Inc., an affiliated company of The Cleveland Clinic, will provide as-needed support during the development process. Other terms of the agreement were not disclosed. Abbott currently markets several cardiac tests for its automated diagnostic analyzers. The ARCHITECT® System offers an acute cardiac panel with tests for Troponin-I, Creatine Kinase-MB (CK-MB) and Myoglobin. Abbott's AxSYM(R) automated immunoassay instrument system also provides a comprehensive cardiac menu with tests for B-type Natriuretic Peptide (BNP), Troponin-I, CK- MB and Myoglobin. About The Cleveland Clinic The Cleveland Clinic Foundation, located in Cleveland, Ohio, is a not-for-profit multispecialty academic medical center that integrates clinical and hospital care with research and education. U.S. News & World Report consistently names The Cleveland Clinic as one of the nation's best hospitals in its annual "America's Best Hospitals" survey. The Cleveland Clinic Lerner Research Institute is ranked fifth in NIH funding among all U.S. research institutes. More than 1,000 scientists work in research programs focusing on cardiovascular, cancer, neurologic, musculoskeletal, allergic and immunologic, eye, metabolic and infectious disease. The Cleveland Clinic Web site address is http://www.clevelandclinic.org . About PrognostiX The Cleveland Clinic launched PrognostiX Inc. in 2003 to develop, validate and commercialize diagnostic tests and treatments based on Cleveland Clinic technologies related to cardiovascular diseases, asthma and other inflammatory diseases. PrognostiX's Web site is http://www.prognostix.com . About Abbott Abbott (NYSE: ABT - News) is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs more than 60,000 people and markets its products in more than 130 countries. Abbott's news releases and other information are available on the company's Web site at http://www.abbott.com . Source: Abbott |
Angioplasty.Org Home • PatientCenter
this press release is posted as a reader
service by Angioplasty.org,
an editorially independent informational health
site
which has received unrestricted educational grants from
Medtronic plc,
TCROSS NEWS, Toshiba
America
Medical Systems, Volcano
Corporation, Terumo
Medical Corporation
Cardium Therapeutics, Inc. and Lenox Hill Heart and Vascular Institute of NY
All content, including text, photos and video
©Copyright Venture Digital LLC 1996-2021
